Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects
Why the study?
Does chronic prostacyclin therapy improve hemodynamics and functional class in patients with pulmonary hypertension and associated congenital heart defects?
Population
20 patients with pulmonary hypertension and associated congenital heart defects who failed conventional…
Design
Case_series
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
May support prostacyclin in refractory congenital heart disease-associated PH; leaves open need for randomized confirmation.
Structured PICO
Does chronic prostacyclin therapy improve hemodynamics and functional class in patients with pulmonary hypertension and associated congenital heart defects?
P
Population
20 patients (mean age 15+/-14 years) with pulmonary hypertension and associated congenital heart defects who failed conventional therapy
I
Intervention
Chronic prostacyclin (PGI2) therapy
O
Outcome
Hemodynamics, NYHA functional class, and exercise capacitysurrogate
Chronic prostacyclin therapy significantly improves hemodynamics and functional class in patients with pulmonary hypertension associated with congenital heart defects who have failed conventional therapy.
Cite This Study
Rosenzweig et al. (1999) studied this question.